Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. - Wikidata - awgldk - TriplyDB

Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

http://www.wikidata.org/entity/Q37072691

about

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma The PI3K/Akt Pathway in Tumors of Endocrine Tissues Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models Upregulated JAG1 enhances cell proliferation in adrenocortical carcinoma Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma.Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors.IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma.Targeted therapies for adrenocortical carcinoma: IGF and beyond.Human adrenocortical carcinoma cell lines.Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.p53 Stabilization induces cell growth inhibition and affects IGF2 pathway in response to radiotherapy in adrenocortical cancer cells MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy.The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial Emerging therapy for adrenocortical carcinoma.Pediatric adrenocortical tumors: what they can tell us on adrenal development and comparison with adult adrenal tumors.Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.Therapy of adrenocortical cancer: present and future.Potent inhibitory effect of the cyclolignan picropodophyllin (PPP) on human adrenocortical carcinoma cells proliferation.Current and emerging therapies for advanced adrenocortical carcinoma.Animal models of adrenocortical tumorigenesis Development of adrenal cortex zonation.Adrenocortical carcinoma: the management of metastatic disease.The insulin and igf-I pathway in endocrine glands carcinogenesis Pregnancy, Primary Aldosteronism, and Adrenal CTNNB1 Mutations.Current and emerging therapeutic options in adrenocortical cancer treatment.GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes.Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression Insulin-like growth factor--phosphatidylinositol 3 kinase signaling in canine cortisol-secreting adrenocortical tumors.ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo.Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer In search of adrenocortical stem and progenitor cells Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.Gene-expression profiling of adrenocortical carcinoma.Genetic aspects of adrenocortical tumours and hyperplasias.Targeted therapy with kinase inhibitors in aggressive endocrine tumors.Genetics and epigenetics of adrenocortical tumors.

P2860

Q24607285-D0D2B8D5-3F67-472A-A602-0B22D8C76480 Q26770404-CCFD07A2-43A9-49BB-B9F9-4610006D6545 Q27021404-CA837A57-1298-4CC5-896B-0F2AF037D5BA Q27321080-7934ACE2-A814-44E3-B3C8-615FA66A6E9A Q28262173-7BA8282A-44F5-4BAF-9D5F-F946DA0189C6 Q33405908-B3E22AB3-4B04-4A77-91DB-7E127B24CB51 Q33892003-07D8450E-5551-4299-80A3-439EA64B356C Q33999643-52BB816E-711E-49F9-B105-D97F9E773D7E Q34101433-F6716A5C-134E-482C-9D0B-F9B40C826BD1 Q34216956-2DC3CABA-0E6D-4B96-8371-B9A9688DE49C Q34391968-4EA75F03-2E81-4954-AFF6-A5FE95B24FA1 Q34428159-C04DCD66-3E0F-4B0D-A677-CF4644837C03 Q34634361-651F46FE-C74B-4814-B214-5ADB7A94FCF7 Q34984126-D3F46128-AAC5-4E5F-83C7-B22F61723CAB Q35018399-60E3A5F9-4796-4DBC-B9A2-6F1AF42535C0 Q35094565-0795C5D0-7DAE-4FC2-8538-80E72440E93F Q35170232-0CF22C56-0909-46F5-AC5E-D34880C3B7CD Q35232257-6B1C798D-331E-47F7-9C59-229727F8E443 Q35232280-1175621C-EF5E-4069-8AAD-DAD052E4C0D1 Q35584305-97A928A5-BF73-419A-B731-71486D08045D Q35784857-82FC0298-FCE1-44A5-A4F3-0D01DF958E50 Q35800278-E2B1E1AD-4F43-4CD4-A0AD-6578EEF3405A Q36081865-FE6269FF-B6AA-47D4-AC34-5F9F718A25E4 Q36178421-10EE9CB5-0D2D-4A39-9808-F93B4C04E271 Q36181540-3616D51B-9D82-498F-8535-7CC566767B26 Q36183873-F57FA818-C9D3-468E-92F2-7E3EF6F37CA5 Q36326358-4EA1E866-B0F2-4F9C-9DAA-9DFE0813D741 Q36357195-A4C74BF2-754C-41E4-AD62-56E15BC2FE25 Q36386448-C5869329-95A2-4E3D-A0A3-D341B7B0F30B Q36772101-2BD56B5E-2CC1-4E90-9C38-61BA6C9CFBC7 Q36873574-5D106EA9-0DE4-4D8B-997D-F682493C6883 Q36951577-4D9E1312-A87A-4C61-9603-D0F029CEF026 Q37212309-53D56572-4575-4138-9AF2-B836FA31A67A Q37298315-CB61C551-B672-4F27-9053-80F35B2DBD99 Q37305066-7BA04C81-964C-4E17-B489-BB84D293FB6C Q37392688-58E224C1-3077-4441-88A9-C991275F55CF Q37481125-AFC746AE-3229-49B2-B5BD-8A0A4E5CD70E Q37999464-B36EC4BE-6C82-46B6-A7C7-8D5031E6CEB2 Q38107011-DA4B57E0-5E2A-4AEC-80E4-7ED695709916 Q38162079-1124E52E-E166-4D88-8AC6-36158869DE50

P2860

Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

http://www.wikidata.org/entity/Q37072691

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Preclinical targeting of the t ...... r in adrenocortical carcinoma.

@en

Preclinical targeting of the t ...... r in adrenocortical carcinoma.

@nl

type

label

Preclinical targeting of the t ...... r in adrenocortical carcinoma.

@en

Preclinical targeting of the t ...... r in adrenocortical carcinoma.

@nl

prefLabel

Preclinical targeting of the t ...... r in adrenocortical carcinoma.

@en

Preclinical targeting of the t ...... r in adrenocortical carcinoma.

@nl

P1433

Q37072691-24764B18-905B-4A67-A384-453A991D4EBE

P1476

Q37072691-854AF9AA-CC56-4846-8CA1-B265FF16B0C5

P2093

Q37072691-39DC5883-38E1-4343-B7D2-5559A13FAAEE

Q37072691-479C5CEA-4E07-4BE8-9893-DACFEB3103CD

Q37072691-59C94B64-4D17-4EFB-BDF5-2803727D0FC2

Q37072691-769060E7-3EB3-44F0-86C0-C55F30B37577

Q37072691-8969FF60-F1A4-4843-9E63-B4702E4A2528

Q37072691-A0ED788F-A7C6-47D9-B875-A1A720AFE7FA

Q37072691-DD943BF3-B2A8-42DF-AED7-5EA3226369B7

P2860

Q37072691-07F2C92B-43F9-4D5C-8738-ED7D98188CF1

Q37072691-14DBAD1F-E85B-4431-9317-AAB9E3A04063

Q37072691-1CC09B62-1263-45DD-B186-33822162AEF1

Q37072691-2336FED8-28E3-4F26-AA2B-1EE04901AB59

Q37072691-28C5EEAE-552A-47C3-BF68-2219374A4E02

Q37072691-3F66EA24-B259-4A98-B9F9-50EA78276AEA

Q37072691-4CB578D3-5540-4785-8E67-E86DF69339AE

Q37072691-6C0A8BD0-835D-40EA-B362-A9C2E0023555

Q37072691-6FF8BC0D-A5AF-4C8E-AB62-321AD73B95F6

Q37072691-7657E201-FBEA-46CE-9D4D-167BF0DB2182

P304

Q37072691-19F8F213-A441-46C6-BAD8-3277ECC20F2D

P31

Q37072691-2655A1D5-1953-422D-8076-67DD43D9841B

P356

Q37072691-2986E695-E49F-4868-B83A-9B174E02335D

P407

Q37072691-DA4E09BC-1D09-404E-93A4-F561DD7882B9

P433

Q37072691-B6FBA3DF-EBCD-4012-989F-107F31623558

P478

Q37072691-C45694A3-7062-451C-A055-3707634C924A

P50

Q37072691-532D1DE5-471F-4531-A534-485B5CD86B02

Q37072691-9EC60B35-740D-46C4-906B-EE713EB95749

P577

Q37072691-0F5DF285-64D3-4DC6-BE57-FE127C7443B5

P698

Q37072691-38295D8C-E8CF-442D-88D6-D5897059EA55

P921

Q37072691-239BC6C0-76B9-413B-831C-ABC0B3C68B65

P932

Q37072691-BA56BC82-53C6-4256-89AE-08294FBDC69B

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Preclinical targeting of the t ...... r in adrenocortical carcinoma.

@en

P2093

Aaron C Spalding

http://www.w3.org/2001/XMLSchema#string

Alex C Kim

http://www.w3.org/2001/XMLSchema#string

Dafydd G Thomas

http://www.w3.org/2001/XMLSchema#string

Ferdous M Barlaskar

http://www.w3.org/2001/XMLSchema#string

Gary D Hammer

http://www.w3.org/2001/XMLSchema#string

Joanne H Heaton

http://www.w3.org/2001/XMLSchema#string

Rork Kuick

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant mitotane treatment for adrenocortical carcinoma

Phenotypic plasticity and the epigenetics of human disease

The epigenetic progenitor origin of human cancer

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

Adrenocortical carcinoma: clinical and laboratory observations.

Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis.

Clinical review: Adrenocortical carcinoma: clinical update.

Adrenocortical carcinoma: diagnosis, evaluation and treatment.

The imprinted H19 noncoding RNA is a primary microRNA precursor

Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis.

P304

204-212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2008-1456

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P50

Edgar Ben-Josef

Thomas Giordano

P577

2008-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18854392

http://www.w3.org/2001/XMLSchema#string

P921

P932

2630877

http://www.w3.org/2001/XMLSchema#string